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ABSTRACT
Resistance to glucocorticoid therapy has been observed in patients
with autoimmune/inflammatory diseases and may be related to the
inflammatory process itself. The aim of this study was to examine the
ability of tumor necrosis factor a (TNFa, a proinflammatory cytokine)
and interleukin (IL)-10 (an anti-inflammatory cytokine) to differen-
tially regulate the sensitivity of human monocytes/macrophages to
glucocorticoids. To accomplish this, we first analyzed the pattern of
TNFa and IL-10 inhibition by dexamethasone in LPS-stimulated
whole-blood cell cultures. Second, we studied the modulation of the
sensitivity of these cells to dexamethasone by preincubation with
TNFa or IL-10 and measurement of LPS-stimulated IL-6 secretion.
In addition, we evaluated the effect of dexamethasone on phorbol-
myristate-acetate-stimulated IL-1 receptor antagonist secretion by
the human monocytic cell line U937. Finally, we investigated whether
the modulation of corticosensitivity in TNFa- and IL-10-pretreated
U937 cells was related to a change of the glucocorticoid receptor
concentration and affinity. Dexamethasone had different effects on
LPS-induced TNFa and IL-10 secretion; whereas it suppressed TNFa
in a dose-dependent fashion, its effect on IL-10 secretion was biphasic,
producing stimulation at lower, and inhibition at higher doses. The
concentration of LPS employed influenced the effect of dexametha-
sone on IL-10 secretion (P , 0.001). Pretreatment with TNFa dimin-
ished, and with IL-10 improved, the ability of dexamethasone to
suppress IL-6 secretion in whole-blood cell cultures (P , 0.01 for both)
and to enhance IL-1 receptor antagonist secretion by U937 cells (P ,
0.05 for both). TNFa decreased (P , 0.001), while IL-10 increased (P ,
0.001), the concentration of dexamethasone binding sites in these
cells, with no discernible effect on their binding affinity. We conclude
that glucocorticoids differentially modulate TNFa and IL-10 secretion
by human monocytes in a LPS dose-dependent fashion and that the
sensitivity of these cells to glucocorticoids is altered by TNFa or IL-10
pretreatment; TNFa blocks their effects, whereas IL-10 acts syner-
gistically with glucocorticoids. This is accompanied by opposite glu-
cocorticoid receptor changes, respectively opposing and favoring glu-
cocorticoid actions. This study suggests that the pattern of pro-/
antiinflammatory cytokine secretion may alter the response of
patients to glucocorticoid therapy. (J Clin Endocrinol Metab 84:
2834–2839, 1999)
GLUCOCORTICOIDS are widely employed in the treat-ment of autoimmune and inflammatory diseases (1).
Varying sensitivity to glucocorticoid therapy has emerged
from the different clinical responses to glucocorticoids
among the multitude of patients with autoimmune/inflam-
matory diseases, on the basis of which they are classified as
corticosteroid-sensitive or corticosteroid-resistant. The re-
sponse of the disease to glucocorticoid therapy depends not
only on the glucocorticoid receptor (GR) concentration and
binding affinity but also on postreceptor mechanisms and
interactions of the GR with DNA hormone-responsive ele-
ments and other nuclear factors, such as AP-1 and NF-kB (2,
3). The glucocorticoid resistance observed in inflammatory
diseases may be induced by the inflammatory process
and/or be genetically or constitutionally determined (4, 5).
Cytokines, the main endocrine, paracrine, and autocrine fac-
tors of the immune/inflammatory response, have been re-
ported to modulate the sensitivity of immune cells to glu-
cocorticoids (6–10).
Tumor necrosis factor a (TNFa, a proinflammatory cyto-
kine) and interleukin (IL)-10 (a T helper 2-type and antiin-
flammatory cytokine) are secreted by activated macrophages
and play opposite roles in both innate and specific immune
responses (11–15). Monocytes/macrophages, as antigen-
presenting cells, are of major importance in the decision for
differentiation of naive Th0 CD41 cells toward Th1- directed
cellular immunity or Th2-directed humoral immunity. Glu-
cocorticoids promote a shift from Th1-type and proinflam-
matory to Th2-type and antiinflammatory cytokine secretory
pattern. This is because the former is strongly inhibited by
glucocorticoids, whereas the latter is not or positively af-
fected (16–19). In this study, we hypothesized that cytokines
could differentially regulate the sensitivity of normal human
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monocytes/macrophages from healthy subjects to glucocor-
ticoids in a fashion that could be influenced by the balance
of proinflammatory/antiinflammatory cytokine secretion.
To test this hypothesis, we first analyzed the pattern of dex-
amethasone-mediated inhibition of TNFa and IL-10 secre-
tion by LPS-stimulated whole-blood cell cultures; and, sec-
ond, we studied the modulation of the dexamethasone
responses of human LPS-stimulated whole-blood cell cul-
tures or of a phorbol-ester-stimulated human monocytic cell
line by preincubation with TNFa or IL-10.
Materials and Methods
Whole-blood cell cultures
Ten healthy male volunteers (age range, 25–45 yr old) served as blood
donors. The blood was treated as previously described (20). The whole-
blood cell cultures were treated as follows: 1) LPS (endotoxin from
Salmonella enteritidis, Sigma Chemical Co., St. Louis, MO) was added
at a final concentration of either 100 pg/mL, 1 ng/mL, or 10 ng/mL. In
whole-blood cell cultures, the mononuclear cells activated by LPS are
mainly monocytes/macrophages. Dexamethasone was added at a final
concentration ranging from 1029–1026 mol/L in separate wells contain-
ing LPS. Plates were incubated at 37 C in 5% CO2. The incubation periods
for LPS-stimulated whole blood were 24 h and 48 h. 2) LPS was added
at a final concentration of 1 ng/mL. Twenty-four hours and 48 h before
LPS stimulation, the whole-blood cell culture was incubated alone or
either in the presence of TNFa (1 ng/mL) or IL-10 (50 pg/mL). Dexa-
methasone was added at a final concentration of 1028 mol/L in separate
wells containing LPS. Plates were incubated at 37 C in 5% CO2. The
incubation period for LPS-stimulated whole blood was 24 h. The con-
tents of the wells were then collected and centrifuged at 900 3 g for 10
min. Supernatants were then recovered and stored at 220 C before
analysis.
Cell line cultures
Two types of clones (plus and minus) of the myeloid monocytic cell
line, U937 cells, were a generous gift from Priscilla Biswas and Guido
Poli (Ospedale San Raffaele, Immunopathogenesis Unit, Milano, Italy).
Cells were maintained in RPMI 1640 (BioWhittaker, Inc. Belgium) with
10% steroid-free heat-inactivated FCS, 100 U/mL penicillin, 100 mg/mL
streptomycin sulfate, and 2 mmol/L glutamine (BioWhittaker, Inc.) at 37
C in 5% CO2. The FCS was treated with 1% dextran-coated charcoal to
remove endogenous sex steroids and glucocorticoids. Cells were
counted and cultured in medium alone or in the presence of TNFa (10
ng/mL) or IL-10 (250 pg/mL) (R&D Systems, UK) for 24 h and 48 h. The
cells were then treated as follows: 1) The cells were removed, counted,
and prepared for whole-cell dexamethasone binding assay; 2) The cells
were stimulated with phorbol-myristate-acetate (PMA), at a final con-
centration of 10 ng/mL, for 24 h, in medium alone or in the presence of
dexamethasone (1028 and 1026 mol/L). The supernatants were then
recovered and stored at 220 C before further analyses.
Whole-cell dexamethasone binding assay
A whole-cell dexamethasone binding assay was used to quantify GR
number and to determine GR affinity in untreated and TNFa- or IL-
10-treated cells. Cells were incubated, in a waterbath at 37 C, for 2 h, at
a final concentration of 107 cells/mL in RPMI 1640 buffer solution
containing 0.5% BSA (Sigma, Belgium) supplemented with seven dif-
ferent concentrations of [3H]-dexamethasone (Amersham International,
Arlington Heights, IL) ranging from 2.5–50 nmol/L (SA, 82 Ci/mmol),
in the presence or in the absence of 1000-fold excess of unlabeled dexa-
methasone (Sigma). After incubation, cells were cooled, centrifuged, and
washed before the supernatant was carefully aspired. Cells were resus-
pended in an equal volume of scintillation cocktail for counting. Dis-
sociation constant (Kd) values and receptor binding capacity were de-
termined on the basis of saturation curves using nonlinear regression
computed with the Prism 2.0 program (GraphPad Software, Inc.). Sta-
tistical analyses were performed on the Scatchard analysis of the same
curves.
Immunoassays
Specific enzyme-linked immunosorbent assays were used to measure
human TNFa, IL-10, and IL-6 (Biosource Technologies, Inc./Medgenix,
Belgium) and IL-1 Ra (receptor antagonist) (R&D Systems) and were
performed according to the manufacturer’s instructions. Absorbency
was transformed to cytokine concentration using a standard curve com-
puted with Medgenix enzyme-linked immunosorbent assay software.
Statistical analyses
The relative changes of cytokine production were computed for each
dexamethasone dose. A logarithmic transformation was used for the
percentage of response, to normalize the distribution. A generalized
linear mixed model (SAS PROC MIXED) was used to analyze the dexa-
methasone general effect and the specific-dose effect on cytokine secre-
tion. All results were considered to be significant at the 5% critical level
(P , 0.05). Statistical analyses were carried out using the SAS software
package (SAS Institute, Inc., Cary, NC). Nonparametric (Mann Withney
and Wilcoxon tests) and parametric tests (Student’s t and ANOVA tests)
were also used for comparisons, as appropriate.
Results
Dexamethasone modulates TNFa and IL-10 secretion in
LPS-stimulated whole-blood cell cultures (Fig. 1)
TNFa and IL-10 secretion were significantly increased in
LPS-stimulated whole-blood cell cultures (P , 0.001). Al-
though both absolute and percent baseline values are shown,
only the statistical comparisons between cytokine levels ex-
pressed as mean percent baseline are reported (Fig. 1, right
panels). TNFa secretion was uniformly suppressed in a dose-
dependent fashion by dexamethasone (1029–1026 mol/L)
after three different concentrations of LPS (Fig. 1, middle and
right panels). Nevertheless, the dexamethasone-induced in-
hibition of TNFa at 1028 and 1027 mol/L was less marked
after 1 and 10 ng than after 0.1 ng LPS stimulation (P , 0.001)
(Fig. 1, right panels). In contrast, the effect of dexamethasone
on IL-10 secretion was biphasic, characterized by stimulation
at the lower doses employed and inhibition at the higher
doses (Fig. 1, left and right panels). LPS dose effects on dexa-
methasone-induced changes in IL-10 secretion were ob-
served; IL-10 was strongly suppressed by dexamethasone
(1028–1026 mol/L) after 0.1 ng LPS stimulation, whereas its
secretion was biphasic after 1 and 10 ng of LPS stimulation
(P , 0.001). After exposure to 1 and 10 ng LPS, there was no
difference in IL-10 modulation by dexamethasone at 1029
and 1028 mol/L; however, a significant difference appeared
at 1027 and 1026 mol/L glucocorticoid (P , 0.01 and P , 0.05,
respectively) (Fig. 1, right panels). At each of the three con-
centrations of LPS employed, the dexamethasone-induced
modulation (1029–1026 mol/L) was significantly different
between IL-10 and TNFa (P , 0.05–0.001). After 0.1 ng LPS,
however, no difference was observed in the dexamethasone-
induced modulation of IL-10 and TNFa secretion at 1027 and
1026 mol/L glucocorticoid (Fig. 1, right panels). The results
were similar at both 24- and 48-h incubations (Fig. 1, right
panels).
TNFa and IL-10 modulate dexamethasone-mediated IL-6
suppression in whole-blood cell cultures (Fig. 2)
We used the same TNFa and IL-10 concentrations that
were observed in LPS-stimulated whole-blood cell cultures
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(1 ng/mL and 50 pg/mL, respectively) (Fig. 1) and investi-
gated whether TNFa or IL-10 preincubation could change the
sensitivity to dexamethasone assessed by dexamethasone-
mediated IL-6 inhibition in whole-blood cell cultures from 10
healthy subjects. The whole-blood cell cultures exposed to
TNFa or IL-10 did not produce IL-6. After LPS stimulation,
however, whole-blood cell cultures not exposed to either
cytokine secreted more IL-6 (399.8 6 29.2 pg/mL) than when
FIG. 1. Dexamethasone effects on the LPS-stimulated secretion of TNFa or IL-10 in whole-blood cell cultures from male normal volunteers.
Data are expressed as mean 6 SEM. Modulation is presented as mean absolute cytokine levels (left and middle panels) and as mean percent
baseline (right panels) after an incubation of 24 h (A) or 48 h (B). The statistical comparisons of cytokine levels are shown only for the mean
percent baseline data (right panels). Dexamethasone suppressed TNFa in a dose-dependent fashion. By contrast, its effect on IL-10 secretion
was biphasic, producing a stimulation at the lower doses employed and an inhibition at the higher doses. At each of the three concentrations
of LPS stimulation employed, the dexamethasone-induced modulation at 1029–1026 mol/L was significantly different between TNFa and IL-10
(*, P , 0.05; **, P , 0.001). A LPS dose-dependent modulation of the IL-10 secretion by dexamethasone from 1028–1026 mol/L was observed:
IL-10 was strongly suppressed after 0.1 ng LPS stimulation by the higher doses of dexamethasone (1028–1026 mol/L), whereas the IL-10
secretion was biphasic after 1 ng and 10 ng LPS stimulation (oo, P , 0.001).
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exposed to TNFa (155.7 6 24.2 pg/mL, P , 0.01) or IL-10
(232.6 6 44.8 pg/mL, P , 0.01). Preincubation with TNFa
was associated with a lower IL-6 secretion than preincuba-
tion with IL-10 (P , 0.01). A longer pretreatment, up to 48 h
before LPS stimulation, was associated with poor IL-6 se-
cretion and did not enable us to assess corticosensitivity. The
dexamethasone-mediated IL-6 inhibition was stronger after
preincubation with IL-10 (18.9 6 1.5%, P , 0.01) and weaker
after preincubation with TNFa (58.5 6 2.1%, P , 0.01) than
with medium alone (41.1 6 1.83%).
TNFa and IL-10 modulate dexamethasone-induced IL-1 Ra
secretion by a human monocytic cell line (Fig. 3)
We examined whether TNFa and IL-10 preincubation
could change the sensitivity to dexamethasone assessed by
dexamethasone-induced IL-1 Ra secretion in the human
monocytic cell line U937. In the baseline condition, IL-1 Ra
secretion was increased after both TNFa (16.4 6 0.9 pg/mL,
P , 0.01) and IL-10 (10.1 6 0.6 pg/mL, P , 0.01) preincu-
bation; no significant difference in the IL-1 Ra level was
observed after these two preincubations. After PMA stimu-
lation, however, dexamethasone-induced IL-1 Ra secretion at
1026 mol/L was higher with IL-10 preincubation (55.7 6 3.5
pg/mL, P , 0.05) and weaker with TNFa preincubation
(14.7 6 1.7 pg/mL, P , 0.05) than with medium alone (23.5 6
3.1 pg/mL). No significant difference was observed between
the IL-1 Ra responses of plus and minus clones of U937 cells.
TNFa decreases, and IL-10 increases, the GR concentration
(but not binding affinity) in a human monocytic cell line
(Fig. 4)
To assess the effect of TNFa and IL-10 on the GR number
and binding affinity, we used dexamethasone radioligand
binding in the human monocytic cell line U937. This was
done to avoid the high variability observed in studies of
isolated peripheral blood mononuclear cells. U937 cells were
cultured, in the absence or presence of TNFa or IL-10, for up
to 48 h; and dexamethasone binding was assessed. No
change in proliferation rate was observed between the dif-
ferent preincubations (data not shown). Both TNFa and IL-10
failed to induce a significant modulation of the GR number
at time periods less than 48 h. However, 48-h exposure to
TNFa resulted in a 60% decrease of the GR number (4,834 6
246 sites/cell vs. 11,709 6 544 sites/cell, P , 0.001) without
any change of the binding affinity (11.4 6 1.5 nmol/L vs.
16.1 6 1.8 nmol/L), whereas exposure to IL-10 resulted in a
50% increase of the GR numbers (17,734 6 87 sites/cell vs.
11,709 6 544 sites/cell, P , 0.001), also without any change
FIG. 2. Low doses of dexamethasone suppressed LPS-induced IL-6
secretion by whole-blood cell cultures pretreated with TNFa or IL-10.
The former diminished (P , 0.01), whereas the latter improved (P ,
0.01), the ability of dexamethasone to suppress IL-6 secretion,
changes compatible with decreased or increased sensitivity to glu-
cocorticoids, respectively.
FIG. 3. Dexamethasone caused a dose-dependent stimulation of IL-
1Ra in human monocytic U937 cells stimulated with PMA. This re-
sponse was decreased by preincubation with TNFa (*, P , 0.05) but
was enhanced by preincubation with IL-10 (*, P , 0.05). Results are
from three independent experiments.
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of the binding affinity (21.5 6 2.4 nmol/L vs. 16.1 6 1.8
nmol/L). The results are summarized on Table 1.
Discussion
Although glucocorticoids clearly suppress proinflamma-
tory cytokines, they have been reported not to change (16,
19), to increase (17), or to decrease IL-10 secretion (18, 21). An
in vivo increase of plasma IL-10 by exogenous glucocorticoids
was previously reported both in human and murine endo-
toxemia (22, 23). Here, we observed a biphasic effect of glu-
cocorticoids on IL-10 secretion by LPS-stimulated whole-
blood cell cultures. Depending on the amplitude of LPS
stimulation, glucocorticoids at low doses increased, and at
high doses decreased, IL-10 secretion; in contrast, TNFa se-
cretion was always suppressed by dexamethasone in a classic
sigmoidal fashion. Thus, the degree of monocyte/macro-
phage activation modulates the effect of dexamethasone on
IL-10 secretion, whereas the direction of the TNFa response
to glucocorticoids remains unchanged. cAMP-elevating
drugs increase IL-10 and decrease TNFa secretion (24), and
cAMP-responsive elements have been described in both the
IL-10 and TNFa promoters (25, 26). The GR interacts with
cAMP-responsive element-binding protein, and this inter-
action may play a role in the differential modulation of IL-10
and TNFa secretion by glucocorticoids (27).
IL-1Ra is a receptor-level natural antagonist of IL-1 that
was isolated from monocytes and monocytic cell lines (28).
Glucocorticoids inhibit IL-1 Ra secretion by LPS-stimulated
human peripheral monocytes (29) but potentiate the IL-1b
secretory response of monocytic cells to PMA (30). The PMA-
differentiated monocytic cell line U937 produces IL-1Ra (31).
Here, we demonstrated that dexamethasone increased
IL-1 Ra secretion by these cells, providing an additional
explanation for an indirect antiinflammatory action for
glucocorticoids.
Preincubation with TNFa or IL-10 modulated the sensi-
tivity to dexamethasone in both normal leukocytes present in
whole-blood cell cultures and U937 cells. Both TNFa and
IL-10 inhibited IL-6 and enhanced IL-1 Ra secretion in the
absence of dexamethasone; however, their effects were in
opposite directions in the presence of dexamethasone. Thus,
whereas IL-6 was more inhibited by TNFa than by IL-10 at
the baseline state, dexamethasone-mediated IL-6 inhibition
was less prominent after TNFa incubation than after IL-10
incubation. Similarly, whereas IL-1 Ra secretion was slightly
more stimulated by TNFa than by IL-10 at the baseline state,
in the presence of dexamethasone, it was blocked by TNFa
and dramatically enhanced by IL-10 preincubation.
IL-10 increased, and TNFa decreased, the GR concentra-
tion of U937 cells without modifying its binding affinity for
dexamethasone. Previously, some cytokines (such as IFNg)
were shown to increase sensitivity of cells to glucocorticoids
by increasing the receptor concentration (6), whereas other
cytokines (such as IL-2, IL-4, and IL-13) decreased sensitivity
by decreasing its binding affinity (7, 8). MIF, the macrophage
migration inhibitory factor, is regulated by glucocorticoids
like IL-10; however, unlike IL-10, it blocks dexamethasone-
mediated inhibition of cytokine production by LPS-stimu-
lated monocytes (10). Our study suggests that IL-10 may
enhance glucocorticoid action by increasing the GR concen-
tration, whereas TNFa may exert the opposite effect by de-
creasing the GR concentration. Changes in the receptor may
be one of several mechanisms for altering tissue sensitivity
TABLE 1. The effect of IL-10 and TNFa on dexamethasone
binding sites in U937 cells
Binding sites/cell (Bmax) Kd (nM)
Control (n 5 3) 11,709 6 544 16.1 6 1.8
IL-10 preincubation (n 5 3) 17,734 6 87a 21.5 6 2.4
TNFa preincubation (n 5 3) 4,834 6 246a 11.4 6 1.5
a Bmax, P , 0.001.
FIG. 4. Saturation analyses and Scat-
chard plots (inset) of [3H]-dexametha-
sone binding in human monocytic U937
cells pretreated with TNFa or IL-10.
The former decreased (*, P , 0.001),
whereas the latter increased (*, P ,
0.001) the concentration of dexametha-
sone binding sites. Results are from
three independent experiments.
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to glucocorticoids (3). Indeed, the modulation of dexameth-
asone response by cytokines may also be related to NF-kB,
which is involved in the transcription of many proinflam-
matory cytokines, including IL-6, and is highly expressed in
inflamed tissues (5). Glucocorticoids and IL-10 inhibit NF-kB
activation, whereas TNFa activates NF-kB (32–34). The op-
posite effect on NF-kB modulation exerted by TNFa and
IL-10 may also provide an additional explanation for the
opposite effects of these cytokines on glucocorticoid sensi-
tivity described here.
In Crohn’s disease, blocking TNFa with humanized anti-
body (cA2) or administering IL-10 were found to be useful
adjunctive therapies (35, 36). Because TNFa decreases, and
IL-10 increases, sensitivity to dexamethasone, this study pro-
vides evidence for another potential beneficial indirect effect
of these cytokine therapies. This also suggests that the bal-
ance of TNFa/IL-10 secretion during the course of an in-
flammatory disease may determine changes in sensitivity to
glucocorticoids. Thus, a patient with a high or low TNFa/
IL-10 ratio would, respectively, be less or more sensitive to
endogenous and exogenous glucocorticoids and more or less
susceptible to develop corticosteroid-resistant and -sensitive
inflammatory disease.
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